Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
alnylam pharmaceuticals
5
×
boston
5
×
boston blog main
boston top stories
fda
5
×
life sciences
5
×
national blog main
patisiran
clinical trials
hereditary transthyretin amyloidosis
national top stories
rna interference
akcea therapeutics
drugs
inotersen
new york blog main
new york top stories
onpattro
san diego blog main
san diego top stories
tafamidis
biotech
pfizer
san francisco blog main
san francisco top stories
vyndaqel
acute hepatic porphyrias
akin akinc
alexion pharmaceuticals
aminolevulinic acid
andrew fire
barry greene
boehringer ingelheim
boston university
craig mello
dan ollendorf
deals
dicerna pharamceuticals
european medicines agency
givosiran
What
alnylam
drug
fda
medicine
pharmaceuticals
rna
rnai
ago
gene
interference
protein
uses
afternoon
alnylam’s
approval
approve
approved
approves
awaits
biological
caught
causing
cells
crossed
decades
decision
dicerna
discovered
disease
ema
employ
europe
eye
fingers
follows
friday
gets
harmful
hepatitis
historic
Language
unset
Current search:
boston
×
fda
×
" alnylam pharmaceuticals "
×
" life sciences "
×
@xconomy.com
4 years ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com
6 years ago
RNAi Hits Europe as EMA Follows FDA, Approves Alnylam Drug
@xconomy.com
6 years ago
Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug
@xconomy.com
6 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision